enVVeno Medical Corporation — Key Metrics
6 years of history · ending 2022-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-2
Book Value Per Share
$3
Free Cash Flow Per Share
$-1
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-1
Return on Equity↓-339.8pts
-53.0%
Return on Assets↑+402.1pts
-49.7%
Return on Invested Capital↓-178.8pts
-42.3%
Current Ratio↑+1283.7% +$24
25.78
Quick Ratio↑+1283.7% +$24
25.78
Asset Turnover↓-95.0% -$0
0.00
Days Sales Outstanding
62.65
Days Payables Outstanding
1262.22
R&D / Revenue↑+5493.7pts
6157.8%
SBC / Revenue↑+4555.8pts
5586.3%
Capex / Revenue↑+64.8pts
71.4%
Working Capital↑+2784.8% +$37M
$38M
Net Current Asset Value↑+2678.1% +$35M
$37M
Invested Capital↑+1801.8% +$37M
$39M
OCF / Net Income↑+29.9% +$0
0.63
FCF / Net Income↑+30.6% +$0
0.64
Accruals Ratio (Sloan)↑+166.1pts
-21.7%
Net Debt↓-1324.6% -$36M
$-39M
Net Debt / EBITDA↑+345.0% +$1
1.58
Interest Coverage
-25.72
Cash Coverage
-20.81
Capex Coverage↑+73.5% +$376
-135.82
Tangible Common Equity↑+2727.0% +$37M
$39M
TCE / Total Assets↑+54.5pts
93.0%
NOPAT↓-217.4% -$13M
$-20M
Cash ROIC↓-173.8pts
-33.8%
WC / Revenue↑+22839.7pts
23544.1%
Capex / D&A↑+482.6% +$0
0.54
Reinvestment Rate↓-1.2pts
0.4%
Asset Growth vs Revenue Growth↓-891.7pts
-775.2%
Revenue 5Y CAGR
-17.5%
Book Value 5Y CAGR
—
Stock Price (FY-end)↓-86.2% -$1K
$179
Market Cap
$2.00B
P/S Ratio
12450.65
P/B Ratio
51.76
P/TB Ratio
51.76
Enterprise Value
$1.97B
EV / Sales
12208.14
FCF Yield
-0.8%
Shareholder Yield
-0.4%
R&D Yield
0.5%
Capex Yield
0.0%
Shares Variation (YoY)
—
Beta (5Y)↑+445.2% +$1
0.86
Cost of Equity↑+3.5pts
8.8%
52W High↓-94.0% -$4K
$274
52W Low↓-90.8% -$1K
$119
Trailing Return 1Y
-19.4%
Trailing Return 5Y
—
F-Score (Piotroski)↑+100.0% +$1
2.00
Z-Score (Altman)
405.75
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.